GlaxoSmithKline: New Clinical Data Shows Efficacy of Fluarix Tetra
06 March 2018 - 11:04PM
Dow Jones News
By Oliver Griffin
GlaxoSmithKline PLC (GSK.LN) said Tuesday that new clinical data
from a phase 3 trial has demonstrated high efficacy of Fluarix
Tetra, an influenza vaccine for young children.
GSK said that Fluarix Tetra prevented influenza types A and
B--acute, highly contagious, respiratory diseases caused by
influenza viruses which are mainly spread through respiratory
droplets.
The company said Fluarix Tetra demonstrated 63.2% vaccine
efficacy against laboratory-confirmed moderate-to-severe influenza,
and efficacy of 49.8% against influenza of any severity in children
aged six months to 35 months.
In culture-confirmed influenza, Fluarix Tetra demonstrated
vaccine efficacy of 77.6% in moderate-to-severe influenza, and
efficacy of 60.1% against influenza of any severity, GSK said.
Write to Oliver Griffin at oliver.griffin@dowjones.com
(END) Dow Jones Newswires
March 06, 2018 06:49 ET (11:49 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024